company background image
ALK B logo

ALK-Abelló CPSE:ALK B Stock Report

Last Price

kr.145.70

Market Cap

kr.32.1b

7D

1.4%

1Y

63.4%

Updated

14 Jun, 2024

Data

Company Financials +

ALK B Stock Overview

Operates as an allergy solutions company in Europe, North America, and internationally.

ALK B fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance5/6
Financial Health6/6
Dividends0/6

ALK-Abelló A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALK-Abelló
Historical stock prices
Current Share Pricekr.145.70
52 Week Highkr.158.90
52 Week Lowkr.69.90
Beta0.58
1 Month Change-6.12%
3 Month Change14.36%
1 Year Change63.43%
3 Year Change-0.75%
5 Year Change80.77%
Change since IPO326.65%

Recent News & Updates

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Jun 07
A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05
ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

Recent updates

A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Jun 07
A Look At The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

May 05
ALK-Abelló A/S (CPH:ALK B) Released Earnings Last Week And Analysts Lifted Their Price Target To kr.143

ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

Apr 27
ALK-Abelló A/S' (CPH:ALK B) Share Price Matching Investor Opinion

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 06
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 29% Below Their Intrinsic Value Estimate

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jan 19
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

Jan 01
With ALK-Abelló A/S (CPH:ALK B) It Looks Like You'll Get What You Pay For

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Sep 09
Is ALK-Abelló (CPH:ALK B) A Risky Investment?

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Jun 11
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

May 24
Is ALK-Abelló A/S (CPH:ALK B) Trading At A 26% Discount?

ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

Mar 12
ALK-Abelló (CPH:ALK B) Has A Pretty Healthy Balance Sheet

ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 17
ALK-Abelló A/S (CPH:ALK B) Shares Could Be 26% Below Their Intrinsic Value Estimate

Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

Jan 30
Investors Interested In ALK-Abelló A/S' (CPH:ALK B) Earnings

ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Dec 05
ALK-Abelló (CPH:ALK B) Seems To Use Debt Rather Sparingly

Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Nov 11
Is ALK-Abelló A/S (CPH:ALK B) Trading At A 32% Discount?

Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Sep 01
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Aug 05
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

May 12
We Think ALK-Abelló (CPH:ALK B) Can Manage Its Debt With Ease

Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Apr 21
Estimating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)

Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Mar 31
Is Now The Time To Put ALK-Abelló (CPH:ALK B) On Your Watchlist?

Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Dec 28
Is ALK-Abelló (CPH:ALK B) A Risky Investment?

Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

Dec 07
Calculating The Intrinsic Value Of ALK-Abelló A/S (CPH:ALK B)

ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

Sep 11
ALK-Abelló (CPH:ALK B) Has A Rock Solid Balance Sheet

Shareholder Returns

ALK BDK PharmaceuticalsDK Market
7D1.4%0.03%-0.1%
1Y63.4%18.7%36.2%

Return vs Industry: ALK B exceeded the Danish Pharmaceuticals industry which returned 18.7% over the past year.

Return vs Market: ALK B exceeded the Danish Market which returned 36.2% over the past year.

Price Volatility

Is ALK B's price volatile compared to industry and market?
ALK B volatility
ALK B Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement4.3%
10% most volatile stocks in DK Market9.8%
10% least volatile stocks in DK Market2.9%

Stable Share Price: ALK B has not had significant price volatility in the past 3 months.

Volatility Over Time: ALK B's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19232,828Peter Hallingwww.alk.net

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

ALK-Abelló A/S Fundamentals Summary

How do ALK-Abelló's earnings and revenue compare to its market cap?
ALK B fundamental statistics
Market capkr.32.14b
Earnings (TTM)kr.555.00m
Revenue (TTM)kr.4.94b

58.1x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALK B income statement (TTM)
Revenuekr.4.94b
Cost of Revenuekr.1.82b
Gross Profitkr.3.13b
Other Expenseskr.2.57b
Earningskr.555.00m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Aug 23, 2024

Earnings per share (EPS)2.51
Gross Margin63.27%
Net Profit Margin11.23%
Debt/Equity Ratio4.2%

How did ALK B perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.